| INTRODUC TI ON
The ultimate goal of the Banff Foundation for Allograft Pathology is to optimize the outcomes of transplant recipients.
1 The universally accepted pathologic-based classification system for antibodymediated rejection (ABMR) formulated by Banff has been a major advancement in the field to increase the awareness of ABMR as an entity and standardize definitions. 
| ME THODS
We performed an international survey of transplant clinicians (nephrologists/transplant surgeons) and renal pathologists to determine how Banff nomenclature 2,3 is interpreted in practice and affects therapeutic decision making. The study was approved by the
Mayo Clinic Research Ethics Board (Rochester, MN).
The survey was distributed by email to members of the , and C4d is negative. There is no interstitial inflammation, tubulitis, transplant glomerulopathy, or tubular atrophy.
Case 3: Chronic active ABMR with de novo DSA and negative C4d
Mr. White is a 45-year-old male with a history of a deceased donor negative cytotoxic crossmatch kidney transplant 10 years ago. It is unknown whether he has any baseline donor-specific antibody. His post transplant course has been relatively unremarkable. His baseline creatinine is 1.5mg/dl (132.63 umol/L) and at a routine follow-up, you find that his creatinine is up to 2.2mg/dl (194.52 umol/L). Urine protein to creatinine ratio is 0.5. Patient is found to have donor-specific antibody -DQ6 with an MFI of 3000. Kidney biopsy shows peritubular capillaritis (ptc score 2), glomerulitis (g score 1), mild transplant glomerulopathy (cg score 1) and C4d is negative. There is no interstitial inflammation, tubulitis, interstitial fibrosis, or tubular atrophy.
Case 4: Histologic features of ABMR without detectable anti-HLA antibody
Ms. Moore is a 62-year-old female with a history of 2 failed kidney transplants. She received a negative flow cytometric crossmatch deceased donor kidney transplant 1 year ago. No donor-specific antibody was identified at the time of transplantation. She comes for routine follow-up visit. Her creatinine is stable at 1.7mg/dl (150.31 umol/L). Her protein to creatinine ratio is 0.6. She does not have any donor-specific antibody. Kidney biopsy shows peritubular capillaritis (ptc 2), glomerulitis (g score 2) and C4d is negative. There is no interstitial inflammation, tubulitis, interstitial fibrosis, or tubular atrophy.
Case 5: Acute/ active ABMR with negative C4d in setting of Positive Crossmatch Transplant and Positive DSA
Mr. Philips is a 56-year-old male with a history of 2 failed kidney transplants. He received a low positive flow cytometric crossmatch (negative CDC crossmatch) deceased donor kidney transplant 6 months ago. Donorspecific antibody was identified at the time of transplant (A2 MFI -2500 and DQ2 MFI -3500). He comes for routine follow-up visit. His creatinine is stable at 1.7mg/dl (150.31 umol/L). His protein to creatinine ratio is 0.6. He continues to have donor-specific antibody (A2 MFI -1500 and DQ2 MFI -4500). Kidney biopsy shows peritubular capillaritis (ptc score 2), glomerulitis (g score 2) and C4d is negative. There is no interstitial inflammation, tubulitis, interstitial fibrosis, or tubular atrophy.
Case 6: Mixed acute T cell mediated rejection and ABMR
Mr. Low is a 35-year-old male who received a negative flow cytometric crossmatch deceased donor kidney transplant 18 months ago. No donor-specific antibody was identified at the time of transplant. He comes in for an urgent visit. His creatinine is up to 2.5mg/dl (221.05 umol/L) from baseline of 1.5mg/dl (132.63 umol/L). Protein/creatinine ratio is 0.2. New donor-specific antibody was identified (A2 MFI -2500 and DQ2 MFI -3500). Kidney biopsy shows peritubular capillaritis (ptc score 2), glomerulitis (g score 1), no transplant glomerulopathy (cg score 0), and C4d is negative. There is also interstitial inflammation and tubulitis consistent with a Banff grade 1B acute cellular rejection.
We provide descriptive statistics on the distribution of diagnoses assigned by the survey participants. For the purposes of this study, the diagnosis chosen by the survey participant was referred to as the assigned diagnosis and the diagnosis agreed upon by the Banff 
| RE SULTS

| Survey respondent characteristics
We received results from 83 pathologists of the 536 who were con- 
| Discordance between respondents diagnoses and reference standard
The diagnosis assigned by the respondent and reference standard differed on average in 26.1% (SD 28.0%) of the cases per pathologist and 34.5% (SD 23.3%) of the cases per clinician (P = .0.04) ( Table 1 ).
Among pathologists, the discordance between the assigned diagno- (Table 1 ).
The assigned diagnosis by pathologists and clinicians had the greatest concordance with the reference standard in the case of mixed a-TCMR and ABMR in the setting of de novo DSA (case 6).
F I G U R E 2 Location and size of respondents' affiliated transplant practice 
| Factors related to discordance
Affiliation with a small (< 100 transplants/year) transplant center was associated with a discordant assigned diagnosis and reference standard in the pathologist group. Specifically, among the assigned diagnoses by pathologists whose affiliated transplant center volume was equal or less than 100 transplants/year; 32.8% (39/119) were different from the reference standard, compared to only 21.3%
(63/296) of diagnoses assigned by pathologists whose affiliated transplant center volume was greater than 100 transplants/year (P = .01). The presence of a Banff chronic glomerulopathy score > 0, allograft dysfunction, C4d positivity, location of transplant center, or de novo DSA were not associated with a discordant assigned diagnosis and reference standard among pathologists. 
TA B L E 1 Interpretation of Banff ABMR classification in clinical practice
| Clinician treatment choices
Clinicians chose a variety of therapeutic approaches for each of the cases as detailed in Tables S1-S6 DSA at the time of transplant (case 5) than when the DSA was de novo In contrast, when chronic active ABMR was assigned, treatment was recommended only 77.7% (SD 39.2%) of the time (P < .0001).
| D ISCUSS I ON
Our study shows that a discrepancy exists in how Banff intended its ABMR classification system to be used and how it is actually interpreted in practice. Pathologists and clinicians alike assigned an ABMR diagnosis that was different from the Banff intended diagnosis approximately 30% of the time. This discrepancy is relevant because the diagnosis assigned by the clinician was associated with the corresponding treatment approach. We acknowledge the difficulty in drawing robust conclusions from survey data, but our results suggest the need for continued diligence to expand educational efforts to increase the awareness and understanding of the ABMR classification in the transplant community.
Further enhancements in the ABMR diagnostic classification system itself may also be needed to increase its applicability and standardization.
Multiple factors likely explain the observed diagnostic discrepancies including the use of an outdated classification or misinterpretation of the current system, the decision not to use the Banff classification, or even the integration of factors not currently part of the Banff classification system (ie, allograft dysfunction) into the diagnosis. Some clinicians lack experience interpreting Banff scores because they routinely rely on the pathologists' final interpretation rather than the individual scores themselves. Moreover, the paucity of large well-designed therapeutic studies in the ABMR field may also decrease the importance of the Banff ABMR classification for some clinicians and/or pathologists.
Another important finding was that treatment approaches for ABMR in general were heterogeneous. (Table 2) .
Importantly, this survey preceded the updated Banff 2017 classification, which includes some important revisions, but it is unclear whether it would have modified the observed diagnostic discrepancies. 4 First, the presence of detected DSA (anti-HLA or non-HLA) is no longer required for an ABMR diagnosis if C4d staining is positive in peritubular capillaries. We believe that this is an important change because of the high specificity for C4d staining time course, antibody characteristics and temporal change, and molecular data will be needed to determine whether these changes lead to more consistent diagnoses and treatments.
We acknowledge that incremental changes in the diagnostic classification system are an improvement but do not adequately address the major needs in this field. Minor changes in the language of the classification system itself will be helpful, but major research efforts are needed to move the Banff system from a discrete diagnostic platform to a prognostic classification system. Providing recommendations to enhance the current diagnostic Banff ABMR classification system by incorporating prognostic features is a long-term goal of our working group (Table 2) 
19,20
The strength of our survey was the unique presentation of clinical scenarios similar to those seen in clinical practice and the survey of a diverse group of clinicians and renal pathologists who practice at transplant centers across the world. This is also the first study to examine how the Banff classification system is interpreted. However, we recognize the limitations of our study given that we relied on survey data. Like other surveys, it was prone to response bias related to the voluntary nature of study participation. The response rate was also relatively low but larger and more comprehensive than similar surveys. 21 The respondents were most likely invested in the diagnosis and treatment of ABMR, and thus the observed diagnostic discrepancies and treatment heterogeneity may underestimate the discrepancies and heterogeneity present in the wider transplant community. Some participants may have been approached more than once because of membership in multiple associations, but known duplicate responses were excluded. A perceived lack of anonymity may have influenced the responses. Additionally, the survey results were also largely descriptive. The study design and relatively low number of respondents limited our ability to consider factors that influenced diagnostic and treatment decisions in multivariable models.
In summary, the current Banff ABMR classification system is vulnerable to misinterpretation in clinical practice, which potentially has patient management implications. Continued efforts are needed to improve knowledge transfer and, consequently, the standardized application of the Banff ABMR classification in the transplant community. Major research efforts are needed in the ABMR field to inform the Banff group and move the current classification system from a discrete diagnostic platform to a prognostic classification system that can be used to inform effective patient care and clinical trial design.
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